Non-alcoholic fatty liver disease (NAFLD) is one the fastest emerging manifestations of the
metabolic syndrome worldwide. Non-alcoholic steatohepatitis (NASH), the progressive form …

Nonalcoholic fatty liver disease (NAFLD) prevalence in women is increasing worldwide.
Women of reproductive age have lower rates of NAFLD compared with men; however, this …

The definable causes of nonalcoholic steatohepatitis (NASH) include jejunoileal bypass
surgery (JIB), other causes of rapid and profound weight loss in obese subjects, total …

Nonalcoholic steatohepatitis (NASH) is a condition characterized by hepatomegaly,
elevated serum aminotransferase levels, and a histologic picture similar to alcoholic …

The lipid content of hepatocytes is regulated by the integrated activities of cellular enzymes
that catalyze lipid uptake, synthesis, oxidation, and export. When``input''of fats into these …

In addition to the usual associations with insulin resistance, type 2 diabetes, central obesity,
and hypertriglyceridemia, nonalcoholic steatohepatitis (NASH) has been associated with …

Objective To assess the incidence, cofactors, and excess risk of development of non-
alcoholic fatty liver disease, including non-alcoholic steatohepatitis, attributable to tamoxifen …

AIM: To clarify the relationship between age, menopause, and nonalcoholic fatty liver
disease (NAFLD) in women. METHODS: We conducted a follow-up study on nonalcoholic …

Hepatic steatosis is a frequent complication in nonobese patients with breast cancer treated
with tamoxifen, a potent antagonist of estrogen. In addition, hepatic steatosis became …

Background Nonalcoholic fatty disease (NAFLD) is the most common liver disease, since it
is strongly associated with obesity and metabolic syndrome pandemics. NAFLD may affect …